Pfizer defends its "50 year" Nigerian record
This article was originally published in Scrip
Pfizer has defended its long history in Nigeria following the publication of the Wikileaks US embassy cable that showed the company in a less than a positive light when it allegedly tried to get the local authorities to drop legal suits around the 1996 trial of the antibiotic, Trovan (trovafloxacin), in which 11 children died.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.